Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 25, 2011

View Archived Issues

Sunnybrook Health Sciences and sanofi-aventis to develop vasculotide

AR-42 displays potent antitumor effects in models of embryonal carcinoma

BMS-936558 shows promise in RCC and mCRPC in phase I trial

Combined GWAS meta-analysis reveals shared genetic risk loci for Crohn's disease and celiac disease

Epidermal growth factor receptor may be marker of progression of penile squamous cancer

CD151 antigen is a marker of prostate cancer recurrence after radical prostatectomy

Vertex reports clinical data on ivacaftor in cystic fibrosis

Enrollment complete in translational clinical study of Reolysin in metastatic colorectal cancer

Bayer and Onyx begin enrollment in phase III Nexavar trial in advanced breast cancer

Evolva demonstrates preclinical efficacy of EV-077 in influenza

FDA approves OraQuick HCV Rapid Antibody Test

Endpoints met in phase Ib trial of TransPharma's ViaDor-GLP-1 agonist in type 2 diabetes

Novo Nordisk submits BLA to FDA for rFXIII in FXIII deficiency

FDA approves label update for Onglyza

NPS Pharma gives product pipeline update

IRM discloses new inhibitors of tyrosine-protein kinase SYK

Merck & Co. discloses new inhibitors of HCV serine protease NS3

Takeda submits NDA to FDA for azilsartan medoxomil plus chlorthalidone

Pharmaxis launches Aridol test kit in U.S. for bronchial hyperresponsiveness

Novartis claims new inhibitors of cyclin-dependent kinase 9

NV Organon patents new glycoprotein hormone FSH receptor agonists

Salix provides update on Xifaxan sNDA for non-constipation-predominant IBS and IBS-related bloating

Ascendis Pharma divulges new prodrugs of pramipexole

Trevena begins phase II TRV-120027 trial in acute heart failure

Isis reports phase I data on C-reactive protein inhibitor ISIS-CRPRx

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...